Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00055471 · ClinicalTrials.gov registry record · Phase 2

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

A Phase 2 study of Prostatic Neoplasms and Metastases, Neoplasm, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
2
Study locations

NCT00055471 is a Phase 2 study of Prostatic Neoplasms and Metastases, Neoplasm that has completed, run by AstraZeneca. The registered enrollment target is 22 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00055471, a Phase 2 study of Prostatic Neoplasms and Metastases, Neoplasm, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

Conditions Studied

Prostatic Neoplasms Metastases, Neoplasm

Interventions

  • DRUG ZD4054 10 mg
  • DRUG ZD4054 15 mg
  • DRUG ZD4054 22.5 mg

Study Locations (2)

Ohio

  • Research Site - Cleveland

Wisconsin

  • Research Site - Madison

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2003-06
Est. Completion 2005-10
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00055471

The ClinicalTrials.gov registry entry for NCT00055471 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Prostatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which ZD4054 10 mg is the first listed.

NCT00055471 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Ohio, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00055471 about?

NCT00055471 is a clinical study titled "A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer". The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer

What is the current status of trial NCT00055471?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2003-06. Estimated completion is 2005-10.

What conditions does trial NCT00055471 study?

This clinical trial studies the following conditions: Prostatic Neoplasms, Metastases, Neoplasm.

What interventions are being tested in trial NCT00055471?

The interventions under investigation include: ZD4054 10 mg (DRUG), ZD4054 15 mg (DRUG), ZD4054 22.5 mg (DRUG).

Who is sponsoring clinical trial NCT00055471?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00055471 being conducted?

This trial has 2 study locations across Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostatic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostatic Neoplasms

All registered trials for this condition

Metastases, Neoplasm

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.